1. Home
  2. GLMD vs REVB Comparison

GLMD vs REVB Comparison

Compare GLMD & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galmed Pharmaceuticals Ltd.

GLMD

Galmed Pharmaceuticals Ltd.

BUY

Current Price

$0.74

Market Cap

4.4M

Sector

Health Care

ML Signal

BUY

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$1.20

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLMD
REVB
Founded
2000
2020
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4M
5.1M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
GLMD
REVB
Price
$0.74
$1.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.8M
65.4K
Earning Date
05-21-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$0.47
52 Week High
$2.67
$3.62

Technical Indicators

Market Signals
Indicator
GLMD
REVB
Relative Strength Index (RSI) 63.49 47.64
Support Level $0.46 $1.06
Resistance Level $0.87 $1.20
Average True Range (ATR) 0.10 0.09
MACD 0.03 0.01
Stochastic Oscillator 38.28 59.09

Price Performance

Historical Comparison
GLMD
REVB

About GLMD Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: